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Abstract
Background: Many areas of pharmaceutical legislation in the European Union (EU) are harmonised in order to
promote the internal market and protect public health. Ideally, harmonisation leads to less fragmented regulation
and cross-border complexities. This study, however, focuses on an increasingly harmonised legislative area that is
subject to increases in requirements and complexities: the distribution of medicines. This study compared Danish
legislation governing the distribution of medicines before and after Denmark joined the EU in order to assess the
impact of EU harmonisation, as well as to evaluate whether the drastic increases in requirements mandated by the
Falsified Medicines Directive of 2011 correspond to a new approach to governing the pharmaceutical supply chain.
Methods: A review was conducted of 115 applicable Danish laws, executive orders and guidelines from 1913 to
2014. Legal requirements were organised according to the year they were published and the companies they
affected. Greater changes in legislative requirements were developed through inductive content analysis.
Results: Early legislation positioned pharmacies as gatekeepers, requiring them to identify and stop medicines of
substandard quality. Legislation to regulate the supply chain was slow to materialise. After Denmark joined the EU,
the scope of legislation widened to include all actors in the supply chain, and the quantity of legislation increased
dramatically. Simultaneously, requirements became more specific, thereby promoting a formalistic interpretation
and focusing the attention of companies and authorities on predefined areas with little room to implement
innovative solutions. Over time, documentation became the focus of legislation, requiring companies to provide
documentary evidence for their compliance with legislation. The Falsified Medicines Directive continues these
trends by increasing requirements for documentation and promoting a formalistic interpretation.
Conclusion: The legislative approach adopted since Denmark joined the EU gives companies and medicine
inspectors little room to interpret legislation. The Falsified Medicines Directive does not depart from this approach.
Legislation seems more focused on enforcing similar requirements than on benefiting public health. Legislation
may benefit from allowing room for local interpretation of requirements.
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Background
The European Union (EU) ensures that the quality, effi-
cacy and safety of pharmaceuticals are regulated by simi-
lar legislation in all EU countries. Pharmaceutical
legislation within the EU is harmonised to allow medi-
cines to travel between EU countries with a minimum of
barriers and to safeguard public health [1, 2]. As a result
of harmonisation, EU member states have limited auton-
omy over the pharmaceutical legislation in their own
country [3]. The EU claims that the harmonised rules
contribute to a high level of safety for consumers [4].
However, others point out that breaking down trade bar-
riers is in effect a deregulatory action likely to have
negative effects on public health [5, 6].
Researchers who argue that harmonisation lowers re-
quirements tend to focus on requirements relating to
the development of medicines and to pay less attention
to legislation governing manufacture and distribution
[7–12]. Although research in the regulation of medi-
cines’ development is important, there may be some-
thing to be learned from looking at other areas of
legislation, such as The Falsified Medicines Directive
(the directive). Published by the EU in 2011, the direct-
ive aims to protect the public from falsified medicines.
The directive imposes strong controls on the supply
chain in order to keep falsified medicines out of Euro-
pean pharmacies. These measures have significant rami-
fications for supply chain actors [13–15], and some
stakeholders, including manufacturers and medicine au-
thorities, have argued that the directive raises the bar
too high [16, 17]. As such, the directive does not seem
to mirror the trend that harmonisation leads to
deregulation.
In an effort to study the effects of EU harmonisation
on the distribution of medicines, an area often ignored
by researchers, this study analysed pharmaceutical legis-
lation in Denmark before and after the country joined
the European Community in 1973. Denmark is a small
EU country with traditionally high regulatory standards,
strong enforcement, a low level of corruption and a long
history of pharmaceutical production.
Based on an historical review of legislation, this paper
identifies characteristics in the developments in Danish
legislation on the distribution of medicines, paying par-
ticular attention to changes after the Danish enrolment
in the EU. In this context, this study examines whether
the measures adopted in the directive introduced a new
approach to governing the pharmaceutical supply chain.
Methods
This study used legislation governing the distribution of
medicines as its empirical material. Although there are
substantial and formal differences between laws, execu-
tive orders and guidelines, these differences will be
ignored in this article. The most effective argument au-
thorities have for enforcing rules in the pharmaceutical
sector – regardless of whether these rules are written in
a law, an executive order, or a guideline – is the threat
of revoking a company’s license to operate. This threat is
only used when a company is overall non-compliant
with the rules. However, rules written in laws, executive
orders and guidelines all matter in the assessment of the
compliance of a company, and they will therefore be re-
ferred to collectively as legislation and treated equally in
this article.
It was decided to analyse past Danish legislation in
order to answer the research question. As the first Da-
nish Pharmacy Act was published in 1913, and due to
the Danish tradition of manufacturing medicines locally
at pharmacies, it was expected that distribution of medi-
cines would be nearly non-existent in the early 1900s.
A documentary search of legislation from 1913 to the
summer of 2014 was conducted to identify legislation gov-
erning the protection of medicines during distribution.
Four different types of government publications were
manually searched for relevant legislation at the Faculty of
Law Library, Copenhagen: Proceedings from the former
and current Parliament (Rigsdagstidende and Folketingsti-
dende) as well as adopted laws (Lovtidende) and executive
orders (Ministerialtidende). Legislation published after
1985 was available through the government website,
www.retsinformation.dk. Danish legislation is indexed ac-
cording to topic of legislation. The keywords used to iden-
tify legislation for this study were “pharmacy” (apotek),
“medicines” (medicin), “pharmaceuticals” (lægemidler),
and “health” (sundhed). Legislation was identified using
the keywords and read by the first author before deciding
whether to include it in the analysis. Documents were ex-
cluded if they did not relate to labelling, storage, distribu-
tion or manufacture of medicines. Documents were also
excluded if they related only to specific types of medicines
(narcotics, veterinary medicines, medical gasses), or, if
reading determined that documents related only to manu-
facturing processes, pharmacy price setting or similar
areas outside the scope of the study. When legislation ref-
erenced other documents (e.g. the pharmacopeia or EU
guidelines), the referenced documents were located via
the library or websites and included in the analysis. A total
of 115 documents were identified as being relevant. Each
document was then registered along with the year it was
published (see Additional file 1).
Analysis
The documents underwent a three-step content analysis
[18]. First, categories relating to handling of medicines
during distribution and storage were inductively devel-
oped through thorough reading of the documents.
Categories were developed to filter out legislative
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requirements related to reimbursement, ownerships of
pharmacies, and other areas irrelevant to this study. A
total of six different categories were developed: pre-
purchase screening, detection (including complaints
handling), stop and recall (including traceability), quality
maintenance, preventing unauthorised handling, and
management. See Table 1 for an explanation of each cat-
egory. The categories were developed by the first author,
presented to two Danish experts in legislation on distri-
bution of medicines, and adjusted according to their
feedback.
The first five categories of ‘Quality Requirements’ all
relate to physical handling of medicines or preventing
the distribution of substandard or falsified medicines.
The category ‘Management’ encompasses requirements
not related to the physical handling of medicines and
not directly affecting the quality of the medicines, but
rather the management of such activities. Although re-
quirements in the category ‘Management’ do not directly
affect the quality of medicines, this category was in-
cluded in the analysis as it was clear even prior to the
analysis that legislation often uses management tools to
regulate the distribution of medicines.
Second, the documents were scrutinised by deduct-
ively identifying legislative requirements related to the
categories and transferred to tables and organised ac-
cording to the year published and the actors to which
they applied. Third, tables were scrutinised by the first
author and greater changes in requirements signalling a
change in scope or adoption of new approaches were
identified and validated via discussions with co-authors.
Particular attention was given to the difference between
the periods before and after Denmark joined the EU.
Results
The first Pharmacy Act was published in 1913, replacing
the existing executive order from 1672. At this time, most
medicines were manufactured locally at pharmacies from
recipes published in the pharmacopeia. However, the in-
dustrial revolution was beginning to have an impact on
the sale of medicines in Denmark. Pharmacies were able
to buy both newly-developed (industrially-produced medi-
cines) and traditional pharmacopeia-based medicines
through foreign and domestic factories [19]. However,
only pharmacopeia-based medicines were regulated in the
beginning (see Fig. 1 for overview of developments).
Prior to the Danish enrolment in the European
Community in 1973, three Pharmacy Acts were pub-
lished approximately every 20 years. They focussed on
pharmacy management and employee education as
the most important tools to ensure high quality medi-
cines, but provided very few details on how pharma-
cies should operate. Domestic factories and importers
were also included in the scope of legislation, but
they received similarly unspecific instructions. Com-
mon for all companies included in the legislation was
the stipulation that they were subject to regular visits
from health authority medicine inspectors. As phar-
macies could only purchase pharmacopeia-based med-
icines from other pharmacies or domestic factories or
importers, the supply chain was kept short and sim-
ple. Pharmacies were held responsible for the quality
of any pharmacopeia-based medicine they sold, re-
gardless of whether they manufactured or purchased
the medicines [19–21].
Although the sales of newly-developed medicines had
surpassed pharmacopeia-based medicines during the
1940s [22], legislation to regulate newly-developed medi-
cines was slow to materialise. The measures taken to
protect the quality of pharmacopeia-based medicines
were not automatically applied to newly-developed med-
icines. For instance, companies manufacturing or distrib-
uting newly-developed medicines were not usually
subject to legislation [21].
Denmark joined the EU (known as the European
Community at the time) in 1973. The process of harmo-
nising legislation with other member states fostered a
new all-encompassing approach to regulating the manu-
facture and distribution of medicines. With the Medi-
cines Act of 1975, legislation centred on the medicines
instead of the pharmacy. The traditional distinction
between pharmacopeia-based and newly-developed
medicines ended. All companies physically handling
medicines, whether through manufacture, storage, distri-
bution or sale, were to be authorised and monitored
through regular visits from medicine inspectors, result-
ing in an increase in the number of companies subject
to legislation (see Table 2) [23].
The quantity of legislation rose remarkably after
Denmark joined the EU (see Fig. 2). The rise in quantity
correlated with increasing specificity of legislative require-
ments, initially in 1977 by establishing requirements for
Table 1 Categories of ‘Quality Requirements’
Category of 'Quality
Requirements'
Purpose of 'Quality Requirement'




To evaluate the quality of received goods.
Stop and recall (including
traceability)
To ensure that distributed products
thought to be substandard or falsified are
stopped or effectively and swiftly recalled.
Quality maintenance To maintain the quality of the product
while in the company’s care.
Preventing unauthorized
handling
To prevent products from moving into
the illegal supply chain.
Management To ensure that company activities are
performed satisfactorily.
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the layout and cleaning of storage areas in order to
maintain the quality of medicines. The same year,
legislation began to require companies to produce
written instructions and to record certain activities
related to the handling of medicines. The focus on
documentation and specificity of legislation continued,
in 1997 resulting in the requirement to establish a
document management system as well as written pro-
cedures describing document handling activities. The
requirement for producing documentation today
encompasses risk assessments of delivery routes, val-
idation reports, auditing reports, training reports,
qualification reports, corrective and preventive action
reports, temperature evaluation reports, etc. As shown
in Fig. 3, the number of different documents (proce-
dures, records, descriptions, evaluation, etc.) required
by legislation has risen dramatically since 1977.
Fig. 1 Timeline of the developments in Danish legislation governing distribution of medicines
Table 2 The expansion of actors in the supply chain subject to
legislation before Danish enrolment in the EU (left) and after
enrolment (right)
Companies subject to Legislation
in 1972 (prior to EU accession)
Companies subject to legislation














Distributors of active pharmaceutical
ingredients
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The falsified medicines directive
The directive was partly implemented in Danish legis-
lation in 2013, most notably introducing requirements
for a new type of company, brokers, which have no
physical contact with medicine, and expanding the
regulated supply chain to include distributors of ac-
tive pharmaceutical ingredients. The main component
of the directive has yet to be implemented: by 2019,
all pharmacies will be required to verify the authenti-
city of medicines before dispensing them by scanning
a unique barcode printed on each package of medi-
cine. The scanner will verify that the unique barcode
is genuine by checking an EU-wide database access-
ible only to pharmaceutical manufacturers, whole-
salers and pharmacies [24]. Data will be stored for
later review by medicine authorities.
Although the specific focus on falsified medicines is
recent, the requirement that pharmacies should only dis-
pense medicines of good quality is by no means new.
The directive may appear drastic to some stakeholders,
but it continues the trends observed in Danish legisla-
tion since Denmark joined the EU, in particular by fo-
cusing on documentation and adding further specificity
to requirements.
Discussion
Danish legislation was harmonised with EU member states
in response to the Danish enrolment into the EU in 1973.
Legislation has since continued to develop according to
three main principles identified in this study: 1) Legislation
has expanded to cover more types of actors, 2) legislative
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Fig. 3 The number of required documents for wholesalers
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documentation has gained increasing importance. The
consequences of these developments are discussed below.
More supply chain actors
The inclusion of different types of supply chain actors pre-
sents challenges, as requirements are rarely the same for
all. Our data show that separate pieces of legislation are
published to cover specific types of actors. Therefore, no
one piece of legislation or one set of requirements applies
to all actors in the supply chain. However, actors in the
supply chain interact with each other, and legislation
needs to regulate their interactions in a way that ensures
the safety of medicines. For example, it is important to
have a clear agreement on who is responsible for the qual-
ity of medicines during transport, the supplier or the pur-
chaser. Similarly, it is important to make sure that a
customer complaint made at a pharmacy is forwarded to
the correct pharmaceutical company for further investiga-
tion. This study found that the legislation regulating the
supply chain as a whole has become highly complex.
Complexity inevitably makes compliance more demanding
and is already forcing companies to hire experts in regula-
tory requirements [25]. As the Organisation for Economic
Co-operation and Development suggested, resources
might be put to better use by eliminating some of the le-
gislative complexity [26].
Specific requirements
The increased specificity of legislation inevitably leads to
a more formalistic interpretation of the rules, which can
have both positive and negative consequences. On the
one hand, specific requirements provide a clear checklist
for authorities when assessing the compliance of com-
panies during inspections, allowing them to focus on
areas predefined as being the most important [27]. This
also translates positively to companies, as they are more
likely to know whether they are in compliance with re-
quirements prior to inspections from authorities [28].
Specific requirements may also make compliance easier
for some companies, as the important areas requiring at-
tention and the level of attention required have already
been identified and described in legislation [29].
On the other hand, some companies may want to
focus on other areas or use strategies other than those
prescribed by legislation. Companies may even want to
change the way they handle medicines entirely. Such
preferences are difficult to accommodate when legisla-
tion sets specific requirements [30]. Specific legislation
therefore carries the risk that innovative and essentially
better or less costly ways of performing tasks will not be
implemented, an argument supported by previous stud-
ies on regulation of pharmaceuticals [31, 32].
Documenting instead of handling medicines
As shown in the analysis, recent requirements focus at-
tention on documentation. By requiring companies to
produce documentation of their compliance, medicine
inspectors are able to discover events of non-compliance
that happened in the past [33]. But as Power [34] de-
scribes, this type of compliance monitoring has a ten-
dency to focus attention on the system of control rather
than on the company’s first order of business.
Companies are required to produce documents that
describe most activities and to provide records to docu-
ment the execution of these activities. Companies are re-
quired to establish elaborate management systems to
manage the documents, as well as allocating employees
to assess and maintain the systems. The resources that
companies expend on complying with the requirements
for document creation and maintenance are most likely
considerable and could potentially be put to more pro-
ductive use.
Harmonisation with enforcement in mind
This study found no signs of the deregulation typically
reported when describing the effects of harmonising
pharmaceutical legislation. On the contrary, require-
ments have increased following the Danish enrolment
into the EU.
The more recent developments identified in this study
promote a uniform enforcement of requirements: spe-
cific requirements promote the enforcement of similar
standards in all member states, and the focus on docu-
menting compliance deters non-compliance. Prior to
joining the EU, Danish legislation was not focused on
enforcement. Medicine inspectors would be unlikely to
discover non-compliance, as requirements were broadly
formulated and companies were not required to keep re-
cords of their activities. Enforcement therefore seems to
have gained increasing importance in Denmark since
joining the EU.
Although enforcement is obviously important, en-
forcement should not be the primary goal of legislation.
Compliance monitoring should be performed using a
minimum of resources, thereby allowing companies to
focus on supplying medicines cheaply and timely while
maintaining their quality. Further, legislation should
allow room for companies and medicine inspectors to
adopt the specific measures most suitable for promoting
public health. Enforcing specific requirements with little
view to the overall goal of legislation, protecting public
health, may provide little value to patients.
This is exemplified in the directive that requires only
prescription medicines to carry unique barcodes, thereby
exempting non-prescription medicines. Although logic-
ally, voluntary use of unique barcodes on non-prescription
medicines would only enhance the protection of public
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health, the European Commission, responsible for the le-
gislation, has insisted on a formalistic interpretation of the
directive and has refused to allow unique barcodes to be
added to non-prescription medicines, even on a voluntary
basis [35].
Hindering use of unique barcodes on medicines might
ultimately lead to the consumption of falsified medicines
by consumers. Such formalistic interpretation allows
companies and EU member states little room to inter-
pret legislation to fit local settings, even if such inter-
pretation benefits public health [36].
The focus on enforcing similar requirements may be
necessary for the EU to ensure the well-functioning of
the internal market. However, it may be beneficial to ad-
just legislation and allow companies and medicine in-
spectors more discretion in implementing legislation.
Recent pharmaceutical legislation may be too focused on
enforcing harmonised requirements, rather than on
making sure that requirements benefit public health. A
similar view has been presented by Permanand [37].
The developments observed corresponds with Wards’
description of New Public Management, where trust is
“replaced by assessment at a distance” [38]. As Abraham
has previously suggested that New Public Management
has shaped pharmaceutical legislation [39], the develop-
ments observed in this study may benefit from being
analysed in such a context.
Conclusions
This study did not find that Danish harmonisation with
the EU caused deregulation. It did find, however, that
the focus of harmonised legislation to enforce similar re-
quirements for all might have unintended side effects.
Rather than allowing companies and medicine inspectors
to focus on protecting public health, harmonised legisla-
tion tends to focus attention on compliance with re-
quirements that do not always fit the situation. This is
exemplified by the Falsified Medicines Directive. There
seems to be a risk that the overall goal of legislation, to
protect public health, could become secondary to the ef-
forts to ensure equal compliance among companies.
Keeping in mind that the protection of public health is
an important goal of member states, we propose that le-
gislation allows companies and medicine inspectors the
possibility to interpret legislative requirements in order
to make decisions that benefit public health.
Additional file




The authors would like to thank our various Nordic colleagues who have
commented on a previous draft of this article.
Funding
No external funding has been received for this study.
Availability of data and material
A list of the documents included in the analysis is included as an Additional
file 1.
Authors’ contributions
RB, SK, TM and JT conceived the idea. RB performed data collection and
analysis. SK, TM and JT verified the analysis. RB wrote the manuscript and SK,
TM and JT revised it. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Pharmacy, University of Copenhagen, Universitetsparken 2,
2100 Copenhagen, Denmark. 2Centre for Information and Innovation Law,
University of Copenhagen, Studiestræde, 1455 Copenhagen, Denmark.
Received: 5 April 2016 Accepted: 4 August 2016
References
1. European Commission. The ‘Blue Guide’ on the implementation of EU
product rules. 2015. Available from: http://ec.europa.eu/DocsRoom/
documents/12661/attachments/1/translations/en/renditions/native.
2. European Union, Directive 2001/83/EC of the European Parliament and of
the Council of 6 November 2001 on the Community code relating to
medicinal products for human use. Official Journal of the European Union.
2001;L33:67.
3. Knill C, Tosun J. Public Policy: A New Introduction. London and New York:
Palgrave MacMillan; 2012.
4. European Commission. Single Market for Goods. 2015. Available from:
http://ec.europa.eu/growth/single-market/goods/index_en.htm.
5. Greer SL, et al. Health law and policy in the European Union. Lancet. 2013;
381(9872):1135–44.
6. Krapohl S. Thalidomide, BSE and the single market: an historical-
institutionalist approach to regulatory regimes in the European Union. Eur J
Polit Res. 2007;46(1):25–46.
7. Norris P. The impact of European harmonisation on Norwegian drug policy.
Health Policy. 1998;43(1):65–81.
8. Vogel D. The globalization of pharmaceutical regulation. Governance. 1998;
11(1):1–22.
9. Abraham J, Lewis G. Harmonising and competing for medicines regulation:
how healthy are the European Union’s systems of drug approval? Soc Sci
Med. 1999;48(11):1655–67.
10. Abraham J, Lewis G. Regulating medicines in Europe: Competition, expertise
and public health. London and New York: Routledge; 2000.
11. Wiktorowicz ME. Emergent patterns in the regulation of pharmaceuticals:
institutions and interests in the United States, Canada, Britain, and France. J
Health Polit Policy Law. 2003;28(4):615–58.
12. Sauer F. European pharmaceutical harmonisation. Pharmaceutical Policy and
Law. 2015;17:9–15.
13. Lisman J. The new EU legislation on falsified medicines: is it a step in the
wrong direction? London: Scrip Regulatory Affairs; 2011. p. 7.
14. Gough P. Drug supply chain assurance issues for industry. London: Scrip
Regulatory Affairs; 2013.
15. Willis C. What the EU has proposed for spotting fake medicines. Pharm J.
2014;292(7813). Online (URI: 20065511).
Borup et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:30 Page 7 of 8
16. Schofield I. UK questions key facets of EU anti-counterfeiting plan. London:
Scrip Regulatory Affairs; 2012.
17. Bruce F. EU generics industry complains of Efpia “misinformation” on
counterfeiting. London: Scrip Regulatory Affairs; 2012.
18. Mayring P. Qualitative Content Analysis. Forum Qualitative Social Research.
2000;1(2). Art. 20. http://nbn-resolving.de/urn:nbn:de:0114-fqs0002204.
19. Danish Parliament. Law No 132 of 29 April 1913 about pharmacies. 1913.
20. Danish Parliament. Law No 107 of 31 March 1932 about pharmacies. 1932.
21. Danish Parliament. Law No. 209 of 11 June 1954 about phamacies. 1954.
22. Ministry of Interior. Report on the pharmacy sector etc. submitted by the
Commission established by the Ministry of Interior on 22 January 1947
(Betænkning vedrørende Apotekervæsenet m.v. Afgivet af den af
Indenrigsministeriet under 22. Januar 1947 nedsatte Kommission). 1952.
23. Danish Parliament. Law no 327 of June 26 1975 on medicines. 1975.
24. European Commission. Draft Commission Delegated Regulation
supplementing Directive 2001/83/EC of the European Parliament and of the
Council by laying down detailed rules for the safety features appearing on





25. Rahalkar H. Historical overview of pharmaceutical industry and drug
regulatory affairs. Pharmaceut Reg Aff. 2012;11:002.
26. OECD. Better Regulation in Europe: Denmark, in Better Regulation in
Europe. 2010.
27. Coglianese C, Nash J, Olmstead T. Performance-based regulation: Prospects
and limitations in health, safety, and environmental protection.
Administrative Law Review. 2003;55:705–29.
28. Burgemeestre B, Hulstijn J, and Tan Y-H. Rule-based versus Principle-based
Regulatory Compliance. London: JURIX; 2009. p. 37-46.
29. Krähenbühl C. Gazing into the crystal ball: What will the EU-FMD safety
features delegated act bring? European Industrial Pharmacy 2014; Available
from: http://eipg.eu/wp-content/uploads/2014/12/eip23-dec14.pdf.
Accessed 02 Oct 2016.
30. Black J. Forms and paradoxes of principles-based regulation. Capital Markets
Law Journal. 2008;3(4):425–57.
31. Cacciatore GG. The overregulation of pharmacy practice. Pharmacotherapy.
1997;17(2):395–6.
32. Price II, WN, Making Do in Making Drugs: Innovation Policy and
Pharmaceutical Manufacturing. Boston College Law Review. 2014;55(2).
http://lawdigitalcommons.bc.edu/bclr/vol55/iss2/5.
33. Day L. What is documentation for? Am J Crit Care. 2009;18(1):77–80.
34. Power M. The audit explosion. London: Demos; 1994.
35. Bogaert PBC. The mysteries of the Falsified Medicines Directive- where is
the logic on safety features? London: Script Regulatory Affairs; 2015. p. 1-3.
36. Kagan RA. Editor’s introduction: understanding regulatory enforcement. Law
Policy. 1989;11(2):89–119.
37. Permanand G, Mossialos E. Constitutional asymmetry and pharmaceutical
policy-making in the European Union. J Eur Public Policy. 2005;12(4):687–709.
38. Ward SC. COMMENTARY: The machinations of managerialism: New public
management and the diminishing power of professionals. J Cult Econ. 2011;
4(2):205–15.
39. Abraham J, Ballinger R. The Neoliberal Regulatory State, Industry Interests,
and the Ideological Penetration of Scientific Knowledge: Deconstructing the
Redefinition of Carcinogens in Pharmaceuticals. Sci Technol Hum Values.
2011;37(5):443–77.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Borup et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:30 Page 8 of 8
